The following content is part of a paid sponsorship and is not an endorsement by CHEST nor does it reflect the views or opinions of CHEST.

Join Insmed for a bronchiectasis Learning Theater exploring the clinical course and pathophysiology of bronchiectasis exacerbations and their impact on disease progression and patient burden

Navigating Bronchiectasis Exacerbations: An Expert Discussion

Join Insmed during the CHEST Annual Meeting 2023 for a Learning Theater featuring prominent bronchiectasis expert Colin Swenson, MD, Medical Director of Respiratory Services and Section Chief of Pulmonary & Critical Care at Emory St Joseph’s Hospital. The event will take place on Wednesday, October 11, from 11:45 AM to 12:30 PM in Learning Theater 2. Boxed lunch will be available.

During this session, Dr Swenson will review data describing the clinical course and pathophysiology of bronchiectasis exacerbations and their impact on disease progression and patient burden. He will also discuss managing bronchiectasis exacerbations in the context of a comprehensive management approach and share his clinical experience in engaging patients in their own care.

Bronchiectasis has been characterized in scientific literature as a vicious cycle or vortex consisting of 4 primary drivers: chronic airway infection, chronic airway inflammation—primarily neutrophilic, impaired mucociliary clearance, and lung destruction.1,2 Within the self-perpetuating cycle of bronchiectasis, each driver can lead to the worsening of the others and contribute to progressive lung damage and exacerbations.1,3

Exacerbations are considered a defining feature of bronchiectasis, even if their specific definition varies across globally published guidelines.4 However, all can agree that exacerbations play a critical role in the progression of disease, with serious consequences for patients.5

Bronchiectasis exacerbations have been associated with lower lung function and worse outcomes, like increased all-cause mortality.5,6 Preventing exacerbations is a key goal of disease management and may help make a positive impact on patients.5,7

To learn more about bronchiectasis and exacerbations, visit Insmed at Booth #1001. We are offering a variety of resources to healthcare professionals throughout CHEST 2023, including an immersive exhibit featuring bronchiectasis research, a 3D lung model, interactive explorations of the science, and more.

The Learning Theater is a non-CME event and does not qualify for CME, CE, or MOC credit. This event is not part of the official CHEST Annual Meeting 2023 conference sessions. This event is not an endorsement by CHEST and does not reflect the views or opinions of CHEST. Meals and transfers of value to US physicians and some other healthcare providers are reportable under applicable federal and state laws and regulations. If you are a healthcare professional licensed in one or more states that place restrictions on meals provided by pharmaceutical companies, we may request that you do not consume any food or beverages provided by Insmed.

References: 1. Flume PA, et al. Lancet. 2018;392(10150):880-890. 2. O’Donnell AE. N Engl J Med. 2022;387(6):533-545. 3. Keir HR, Chalmers JD. Semin Respir Crit Care Med. 2021;42(4):449-512. 4. Hill AT, et al. Eur Respir J. 2017;49(6):1700051. 5. Chalmers JD, et al. Am J Respir Crit Care Med. 2018;197(11):1410-1420. 6. Chalmers JD, et al. Am J Respir Crit Care Med. 2014;189(5):576-585. 7. Chalmers JD, et al. Nat Rev Dis Primers. 2018;4(1):45.

© 2023 Insmed Incorporated. All Rights Reserved. Insmed is a trademark of Insmed Incorporated. All other trademarks are property of their respective owner. NP-BE-US-00272